Update on JNK inhibitor patents: 2015 to present.
Expert Opin Ther Pat
; 34(10): 907-927, 2024 Oct.
Article
em En
| MEDLINE
| ID: mdl-39223788
ABSTRACT
INTRODUCTION:
c-Jun N-terminal kinase (JNK) regulates various biological processes through the phosphorylation cascade and is closely associated with numerous diseases, including inflammation, cardiovascular diseases, and neurological disorders. Therefore, JNKs have emerged as potential targets for disease treatment. AREAS COVERED This review compiles the patents and literatures concerning JNK inhibitors through retrieving relevant information from the SciFinder, Google Patents databases, and PubMed from 2015 to the present. It summarizes the structure-activity relationship (SAR) and biological activity profiles of JNK inhibitors, offering valuable perspectives on their potential therapeutic applications. EXPERT OPINION The JNK kinase serves as a novel target for the treatment of neurodegenerative disorders, pulmonary fibrosis, and other illnesses. A variety of small-molecule inhibitors targeting JNKs have demonstrated promising therapeutic potential in preclinical studies, which act upon JNK kinases via distinct mechanisms, encompassing traditional ATP competitive inhibition, covalent inhibition, and bidentate inhibition. Among them, several JNK inhibitors from PregLem SA, Celegene SA, and Xigen SA have accomplished the early stage of clinical trials, and their results will guide the development and indications of future JNK inhibitors.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Patentes como Assunto
/
Proteínas Quinases JNK Ativadas por Mitógeno
/
Inibidores de Proteínas Quinases
/
Desenvolvimento de Medicamentos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Ther Pat
/
Expert opin. ther. pat
/
Expert opinion on therapeutic patents
Assunto da revista:
TERAPEUTICA
Ano de publicação:
2024
Tipo de documento:
Article
País de publicação:
Reino Unido